Acute HIV Infection Presenting With Diffuse Plaque Psoriasis Treated With Highly Active Antiretroviral Therapy
- PMID: 34976468
- PMCID: PMC8681926
- DOI: 10.7759/cureus.19680
Acute HIV Infection Presenting With Diffuse Plaque Psoriasis Treated With Highly Active Antiretroviral Therapy
Abstract
Cutaneous diseases such as psoriasis are often the first disease manifestations in HIV+ patients, with greater severity corresponding to a weaker immune system. Despite its prevalence, literature and placebo-controlled studies on the recognition of HIV as a cause of psoriasis are lacking, causing challenges to arise in its treatment. In this article, we illustrate a case of an HIV+ patient whose psoriasis drastically improved after the initiation of highly active antiretroviral therapy (HAART) consisting of bictegravir, emtricitabine, and tenofovir alafenamide. While it is unclear which combination of antiretrovirals is optimal for controlling psoriasis in HIV+ patients, prompt initiation of HAART can significantly improve immune status and psoriasis in HIV+ patients.
Keywords: acute hiv infection; acute retroviral syndrome; diffuse psoriasis; haart; hiv symptoms; viral exanthem.
Copyright © 2021, Bressler et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
Similar articles
-
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.Lancet HIV. 2019 Jun;6(6):e364-e372. doi: 10.1016/S2352-3018(19)30080-3. Epub 2019 May 5. Lancet HIV. 2019. PMID: 31068272 Clinical Trial.
-
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.Lancet. 2017 Nov 4;390(10107):2073-2082. doi: 10.1016/S0140-6736(17)32340-1. Epub 2017 Aug 31. Lancet. 2017. PMID: 28867499 Clinical Trial.
-
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.Lancet HIV. 2017 Apr;4(4):e154-e160. doi: 10.1016/S2352-3018(17)30016-4. Epub 2017 Feb 15. Lancet HIV. 2017. PMID: 28219610 Clinical Trial.
-
Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.Drugs. 2018 Nov;78(17):1817-1828. doi: 10.1007/s40265-018-1010-7. Drugs. 2018. PMID: 30460547 Free PMC article. Review.
-
Molecular biological assessment methods and understanding the course of the HIV infection.APMIS Suppl. 2003;(114):1-37. APMIS Suppl. 2003. PMID: 14626050 Review.
References
-
- Psoriasis prevalence among adults in the United States. Rachakonda TD, Schupp CW, Armstrong AW. J Am Acad Dermatol. 2014;70:512–516. - PubMed
-
- Particular clinical presentations of psoriasis in HIV patients. Fernandes S, Pinto GM, Cardoso J. Int J STD AIDS. 2011;22:653–654. - PubMed
-
- Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. Menon K, Van Voorhees AS, Bebo BF Jr, et al. J Am Acad Dermatol. 2010;62:291–299. - PubMed
-
- HIV-associated psoriasis: epidemiology, pathogenesis, and management. Ceccarelli M, Venanzi Rullo E, Vaccaro M, et al. Dermatol Ther. 2019;32:0. - PubMed
-
- Cutaneous markers of HIV infection. Rigopoulos D, Paparizos V, Katsambas A. Clin Dermatol. 2004;22:487–498. - PubMed
Publication types
LinkOut - more resources
Full Text Sources